Skip to content
Peptidepedia

TB-500 Results: Timeline, Before & After & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Results Timelines

Weeks 1–2:

  • Some users report initial reductions in inflammation and mild improvements in comfort at injury sites

Weeks 2–4:

  • Many individuals begin noticing improvements in mobility, recovery speed, and energy levels

Weeks 4–8:

  • More substantial improvements in tissue repair, flexibility, and functional recovery are commonly reported during this period

Months 2–6:

  • Long-term benefits often continue to build with consistent use, particularly for chronic injuries or conditions requiring extended healing time

Frequently Asked Questions

Most users report initial improvements within 2–4 weeks, with more substantial benefits developing over 4–8 weeks of consistent use. Timelines vary based on injury severity, individual physiology, and dosing protocols.

Clinical trials of thymosin beta-4 have demonstrated that it is safe and well-tolerated at therapeutic doses in animals. However, long-term safety data specifically for TB-500 in humans is limited, and potential risks from unregulated products include contamination and inconsistent dosing.

Unreconstituted TB-500 should be refrigerated or stored in a cool, dry place. Once reconstituted with bacteriostatic water, it must be refrigerated at 2–8°C and used within 3–4 weeks.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Goldstein AL, Kleinman HK. Minireview: Crosstalk between thymosin β4 and the chemokine network. Ann N Y Acad Sci. 2015.
  2. Philp D, Kleinman HK. Animal studies with thymosin β4, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 2012.
  3. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999.
  4. Smart N, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007.
  5. RegeneRx Biopharmaceuticals. Phase II Clinical Trials: Thymosin Beta-4 for Dermal Wound Healing.
  6. World Anti-Doping Agency. The 2024 Prohibited List International Standard.
  7. Drip Hydration. The Wolverine Stack: Can BPC 157 and TB 500 Accelerate Injury Recovery?
  8. Examine.com. Thymosin Beta-4 Research Breakdown.
  9. U.S. Food and Drug Administration. Bulk Drug Substances Under Evaluation for Use in Compounding Under Section 503A.
←Read the full TB-500 guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”